Sanjeev Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sanjeev Kumar has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Aldi Chan
Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California
5 shared publications - Brijesh Kumar Singh
Cellular and Molecular Neuroscience Laboratory, National Brain Research Centre, Manesar, Gurgaon 122 050, India
5 shared publications - Bryanna Reinhardt
Division of Hematology & Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California
5 shared publications - Dana H. Tran
Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois
5 shared publications - Elena B. Pasquale
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA
5 shared publications - Gary J. Schiller
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
5 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (7) , e1952
CTLA4-Ig + Anti-IL-6/IL-6R Treatment Results in Long-term Allograft Survival and Function in Highly HLA-sensitized Patients
Background.: Highly HLA-sensitized (HS) patients are at increased risk for cell-mediated rejection (CMR)/antibody-mediated rejection (AMR) posttransplant and require intense immunosuppression to prevent these events. HS patients who experience calcineurin inhibitor (CNI) neuro/nephrotoxicity have few options as conversion to CNI-free regimens with cytotoxic T-lymphocyte-associated antigen (CTLA4)-Ig may risk donor specific antibody (DSA) rebound, CMR, and AMR. This remains an unmet medical need. Anti-interleukin (IL)-6/IL-6R treatment is useful in treating AMR and CMR and preventing rejection in HS patients after transplantation (tx). Here, we examined the utility of combining CTLA4-Ig with anti-IL-6/IL-6R treatment in 4 HS patients with CNI toxicity. Methods.: Four HS patients (3 with calculated panel reactive antibodies >97% at tx and 1 who developed chronic-active AMR (c-aAMR) 14 y post-tx were evaluated. Two patients, 100% calculated panel reactive antibody and +flow crossmatch at transplantation, were desensitized with plasma exchange + clazakizumab (anti-IL-6) and maintained on clazakizumab post-tx and transitioned from CNI to CTLA4-Ig. Two patients treated with anti-IL-6R (tocilizumab) were transitioned to CTLA4-Ig at 2 and 11 y post-tx. Patients were monitored for renal function (RF), DSA, de novo DSA (dn-DSA), immune cell subsets, and patient and graft survival. Results.: Clazakizumab and tocilizumab treated patients showed improvements in RF, with elimination of existing DSAs, except for 1 patient and no dn-DSAs (>6 y). We also saw reductions in CD8 + T EFF/MEM , T FH , B MEM , and NK cells post-CTLA4-Ig + Anti-IL-6/IL-6R treatment. T REG and B REG cell populations also increased, suggesting, but not confirming, possible immune modulation. Conclusions.: Combining CTLA4-Ig + anti-IL-6/IL-6R appears to offer benefits in sustaining RF, DSA reduction, possibly immune cell modulation, and prevention of dn-DSA. Importantly, CNI toxicity abated in all patients.
- 2 June 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (7) , e1952
Open AccessCTLA4-Ig + Anti-IL-6/IL-6R Treatment Results in Long-term Allograft Survival and Function in Highly HLA-sensitized Patients
Background.: Highly HLA-sensitized (HS) patients are at increased risk for cell-mediated rejection (CMR)/antibody-mediated rejection (AMR) posttransplant and require intense immunosuppression to prevent these events. HS patients who experience calcineurin inhibitor (CNI) neuro/nephrotoxicity have few options as conversion to CNI-free regimens with cytotoxic T-lymphocyte-associated antigen (CTLA4)-Ig may risk donor specific antibody (DSA) rebound, CMR, and AMR. This remains an unmet medical need. Anti-interleukin (IL)-6/IL-6R treatment is useful in treating AMR and CMR and preventing rejection in HS patients after transplantation (tx). Here, we examined the utility of combining CTLA4-Ig with anti-IL-6/IL-6R treatment in 4 HS patients with CNI toxicity. Methods.: Four HS patients (3 with calculated panel reactive antibodies >97% at tx and 1 who developed chronic-active AMR (c-aAMR) 14 y post-tx were evaluated. Two patients, 100% calculated panel reactive antibody and +flow crossmatch at transplantation, were desensitized with plasma exchange + clazakizumab (anti-IL-6) and maintained on clazakizumab post-tx and transitioned from CNI to CTLA4-Ig. Two patients treated with anti-IL-6R (tocilizumab) were transitioned to CTLA4-Ig at 2 and 11 y post-tx. Patients were monitored for renal function (RF), DSA, de novo DSA (dn-DSA), immune cell subsets, and patient and graft survival. Results.: Clazakizumab and tocilizumab treated patients showed improvements in RF, with elimination of existing DSAs, except for 1 patient and no dn-DSAs (>6 y). We also saw reductions in CD8 + T EFF/MEM , T FH , B MEM , and NK cells post-CTLA4-Ig + Anti-IL-6/IL-6R treatment. T REG and B REG cell populations also increased, suggesting, but not confirming, possible immune modulation. Conclusions.: Combining CTLA4-Ig + anti-IL-6/IL-6R appears to offer benefits in sustaining RF, DSA reduction, possibly immune cell modulation, and prevention of dn-DSA. Importantly, CNI toxicity abated in all patients.
- 30 December 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (2) , 220-222
Probing Molecular Mechanisms of Proximal Tubular Resilience and Repair
- 30 December 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (2) , 220-222
Probing Molecular Mechanisms of Proximal Tubular Resilience and Repair
- Open Access
- 5 December 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 426-434
Kidney Biorepositories
Biorepositories—centralized facilities for storing biologic specimens (such as blood, urine, and tissue) along with associated patient data—are critical resources that can drive progress in AKI research. To highlight their importance, the American Society of Nephrology's AKINow Basic Science Workgroup hosted a webinar titled “ How to Build and Best Use Kidney Biorepositories ,” featuring expert panelists Drs. A. Hung, S. Jain, and C. Parikh. This discussion, summarized here, focused on: ( 1 ) How biorepositories can support research, especially for early-stage investigators; ( 2 ) key logistical considerations for establishing a new biorepository; and ( 3 ) the benefits and trade-offs of creating a new biorepository versus existing ones. In addition, details related to existing biorepositories are provided to foster better utilization of these valuable resources. The goal is to inform nephrology investigators about how to leverage existing biorepositories to advance their research and to provide guidance for those interested in generating their own.
- 5 December 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 426-434
Open AccessKidney Biorepositories
Biorepositories—centralized facilities for storing biologic specimens (such as blood, urine, and tissue) along with associated patient data—are critical resources that can drive progress in AKI research. To highlight their importance, the American Society of Nephrology's AKINow Basic Science Workgroup hosted a webinar titled “ How to Build and Best Use Kidney Biorepositories ,” featuring expert panelists Drs. A. Hung, S. Jain, and C. Parikh. This discussion, summarized here, focused on: ( 1 ) How biorepositories can support research, especially for early-stage investigators; ( 2 ) key logistical considerations for establishing a new biorepository; and ( 3 ) the benefits and trade-offs of creating a new biorepository versus existing ones. In addition, details related to existing biorepositories are provided to foster better utilization of these valuable resources. The goal is to inform nephrology investigators about how to leverage existing biorepositories to advance their research and to provide guidance for those interested in generating their own.
- Open Access
Cellular and Spatial Drivers of Unresolved Injury and Functional Decline in the Human Kidney
Building upon a foundational Human Kidney resource, we present a comprehensive multi-modal atlas that defines spatially resolved versus unresolved repair states and mechanisms in human kidney disease. Homeostatic interactions between injured kidney epithelium and its surrounding milieu determine successful repair outcomes, while pathogenic signaling promotes unresolved inflammation and fibrosis leading to chronic disease. We integrated multiple single-cell and spatial modalities across ∼700 samples from >350 patients (∼250 research biopsies), analyzing ∼1.7 million cells alongside complementary mouse multi-omic profiles spanning acute-to-chronic injury and aging (>300,000 cells) and spatial transcriptomic analysis of >150 human biopsies. This cross-species atlas delineates functional pathways and druggable targets across the nephron and defines gene regulatory networks and chromatin landscapes governing tubular, fibroblast, and immune cell transitions from injury to either recovery or failed repair states. We identified distinct cellular states associated with specific pathological features that show dynamic distributions between acute kidney injury (AKI) and chronic kidney disease (CKD), organized within unique spatial niches that reveal progression mechanisms from early injury to unresolved disease. Gene regulatory analyses prioritized key transcription factor activities (SOX4, SOX9, NFKB1, REL, KLFs) and their target networks establishing disease states and tissue microenvironments. These regulatory programs were directly linked to clinical outcomes, identifying molecular signatures of recovery and secreted biomarkers predictive of AKI-to-CKD progression, providing a key resource for therapeutic development and precision medicine approaches in kidney disease.
Open AccessCellular and Spatial Drivers of Unresolved Injury and Functional Decline in the Human Kidney
Building upon a foundational Human Kidney resource, we present a comprehensive multi-modal atlas that defines spatially resolved versus unresolved repair states and mechanisms in human kidney disease. Homeostatic interactions between injured kidney epithelium and its surrounding milieu determine successful repair outcomes, while pathogenic signaling promotes unresolved inflammation and fibrosis leading to chronic disease. We integrated multiple single-cell and spatial modalities across ∼700 samples from >350 patients (∼250 research biopsies), analyzing ∼1.7 million cells alongside complementary mouse multi-omic profiles spanning acute-to-chronic injury and aging (>300,000 cells) and spatial transcriptomic analysis of >150 human biopsies. This cross-species atlas delineates functional pathways and druggable targets across the nephron and defines gene regulatory networks and chromatin landscapes governing tubular, fibroblast, and immune cell transitions from injury to either recovery or failed repair states. We identified distinct cellular states associated with specific pathological features that show dynamic distributions between acute kidney injury (AKI) and chronic kidney disease (CKD), organized within unique spatial niches that reveal progression mechanisms from early injury to unresolved disease. Gene regulatory analyses prioritized key transcription factor activities (SOX4, SOX9, NFKB1, REL, KLFs) and their target networks establishing disease states and tissue microenvironments. These regulatory programs were directly linked to clinical outcomes, identifying molecular signatures of recovery and secreted biomarkers predictive of AKI-to-CKD progression, providing a key resource for therapeutic development and precision medicine approaches in kidney disease.
- Open Access
- 9 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (9) , 1926-1939
Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial
- 9 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (9) , 1926-1939
Open AccessBack-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis
Bone marrow vascular endothelial cells (BM EC) regulate multiple myeloma pathogenesis. Identification of the mechanisms underlying this interaction could lead to the development of improved strategies for treating multiple myeloma. Here, we performed a transcriptomic analysis of human ECs with high capacity to promote multiple myeloma growth, revealing overexpression of the receptor tyrosine kinases, EPHB1 and EPHB4, in multiple myeloma–supportive ECs. Expression of ephrin B2 (EFNB2), the binding partner for EPHB1 and EPHB4, was significantly increased in multiple myeloma cells. Silencing EPHB1 or EPHB4 in ECs suppressed multiple myeloma growth in coculture. Similarly, loss of EFNB2 in multiple myeloma cells blocked multiple myeloma proliferation and survival in vitro, abrogated multiple myeloma engraftment in immune-deficient mice, and increased multiple myeloma sensitivity to chemotherapy. Administration of an EFNB2-targeted single-chain variable fragment also suppressed multiple myeloma growth in vivo. In contrast, overexpression of EFNB2 in multiple myeloma cells increased STAT5 activation, increased multiple myeloma cell survival and proliferation, and decreased multiple myeloma sensitivity to chemotherapy. Conversely, expression of mutant EFNB2 lacking reverse signaling capacity in multiple myeloma cells increased multiple myeloma cell death and sensitivity to chemotherapy and abolished multiple myeloma growth in vivo. Complementary analysis of multiple myeloma patient data revealed that increased EFNB2 expression is associated with adverse-risk disease and decreased survival. This study suggests that EFNB2 reverse signaling controls multiple myeloma pathogenesis and can be therapeutically targeted to improve multiple myeloma outcomes.Significance:Ephrin B2 reverse signaling mediated by endothelial cells directly regulates multiple myeloma progression and treatment resistance, which can be overcome through targeted inhibition of ephrin B2 to abolish myeloma.
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis
Bone marrow vascular endothelial cells (BM EC) regulate multiple myeloma pathogenesis. Identification of the mechanisms underlying this interaction could lead to the development of improved strategies for treating multiple myeloma. Here, we performed a transcriptomic analysis of human ECs with high capacity to promote multiple myeloma growth, revealing overexpression of the receptor tyrosine kinases, EPHB1 and EPHB4, in multiple myeloma–supportive ECs. Expression of ephrin B2 (EFNB2), the binding partner for EPHB1 and EPHB4, was significantly increased in multiple myeloma cells. Silencing EPHB1 or EPHB4 in ECs suppressed multiple myeloma growth in coculture. Similarly, loss of EFNB2 in multiple myeloma cells blocked multiple myeloma proliferation and survival in vitro, abrogated multiple myeloma engraftment in immune-deficient mice, and increased multiple myeloma sensitivity to chemotherapy. Administration of an EFNB2-targeted single-chain variable fragment also suppressed multiple myeloma growth in vivo. In contrast, overexpression of EFNB2 in multiple myeloma cells increased STAT5 activation, increased multiple myeloma cell survival and proliferation, and decreased multiple myeloma sensitivity to chemotherapy. Conversely, expression of mutant EFNB2 lacking reverse signaling capacity in multiple myeloma cells increased multiple myeloma cell death and sensitivity to chemotherapy and abolished multiple myeloma growth in vivo. Complementary analysis of multiple myeloma patient data revealed that increased EFNB2 expression is associated with adverse-risk disease and decreased survival. This study suggests that EFNB2 reverse signaling controls multiple myeloma pathogenesis and can be therapeutically targeted to improve multiple myeloma outcomes.Significance:Ephrin B2 reverse signaling mediated by endothelial cells directly regulates multiple myeloma progression and treatment resistance, which can be overcome through targeted inhibition of ephrin B2 to abolish myeloma.
- Open Access
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis
Bone marrow vascular endothelial cells (BM EC) regulate multiple myeloma pathogenesis. Identification of the mechanisms underlying this interaction could lead to the development of improved strategies for treating multiple myeloma. Here, we performed a transcriptomic analysis of human ECs with high capacity to promote multiple myeloma growth, revealing overexpression of the receptor tyrosine kinases, EPHB1 and EPHB4, in multiple myeloma–supportive ECs. Expression of ephrin B2 (EFNB2), the binding partner for EPHB1 and EPHB4, was significantly increased in multiple myeloma cells. Silencing EPHB1 or EPHB4 in ECs suppressed multiple myeloma growth in coculture. Similarly, loss of EFNB2 in multiple myeloma cells blocked multiple myeloma proliferation and survival in vitro, abrogated multiple myeloma engraftment in immune-deficient mice, and increased multiple myeloma sensitivity to chemotherapy. Administration of an EFNB2-targeted single-chain variable fragment also suppressed multiple myeloma growth in vivo. In contrast, overexpression of EFNB2 in multiple myeloma cells increased STAT5 activation, increased multiple myeloma cell survival and proliferation, and decreased multiple myeloma sensitivity to chemotherapy. Conversely, expression of mutant EFNB2 lacking reverse signaling capacity in multiple myeloma cells increased multiple myeloma cell death and sensitivity to chemotherapy and abolished multiple myeloma growth in vivo. Complementary analysis of multiple myeloma patient data revealed that increased EFNB2 expression is associated with adverse-risk disease and decreased survival. This study suggests that EFNB2 reverse signaling controls multiple myeloma pathogenesis and can be therapeutically targeted to improve multiple myeloma outcomes.Significance:Ephrin B2 reverse signaling mediated by endothelial cells directly regulates multiple myeloma progression and treatment resistance, which can be overcome through targeted inhibition of ephrin B2 to abolish myeloma.
- 15 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis
Bone marrow vascular endothelial cells (BM EC) regulate multiple myeloma pathogenesis. Identification of the mechanisms underlying this interaction could lead to the development of improved strategies for treating multiple myeloma. Here, we performed a transcriptomic analysis of human ECs with high capacity to promote multiple myeloma growth, revealing overexpression of the receptor tyrosine kinases, EPHB1 and EPHB4, in multiple myeloma–supportive ECs. Expression of ephrin B2 (EFNB2), the binding partner for EPHB1 and EPHB4, was significantly increased in multiple myeloma cells. Silencing EPHB1 or EPHB4 in ECs suppressed multiple myeloma growth in coculture. Similarly, loss of EFNB2 in multiple myeloma cells blocked multiple myeloma proliferation and survival in vitro, abrogated multiple myeloma engraftment in immune-deficient mice, and increased multiple myeloma sensitivity to chemotherapy. Administration of an EFNB2-targeted single-chain variable fragment also suppressed multiple myeloma growth in vivo. In contrast, overexpression of EFNB2 in multiple myeloma cells increased STAT5 activation, increased multiple myeloma cell survival and proliferation, and decreased multiple myeloma sensitivity to chemotherapy. Conversely, expression of mutant EFNB2 lacking reverse signaling capacity in multiple myeloma cells increased multiple myeloma cell death and sensitivity to chemotherapy and abolished multiple myeloma growth in vivo. Complementary analysis of multiple myeloma patient data revealed that increased EFNB2 expression is associated with adverse-risk disease and decreased survival. This study suggests that EFNB2 reverse signaling controls multiple myeloma pathogenesis and can be therapeutically targeted to improve multiple myeloma outcomes.Significance:Ephrin B2 reverse signaling mediated by endothelial cells directly regulates multiple myeloma progression and treatment resistance, which can be overcome through targeted inhibition of ephrin B2 to abolish myeloma.
- Top Cited Papers
- 23 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 383 (6685) , eadd6371
SOX9 switch links regeneration to fibrosis at the single-cell level in mammalian kidneys
The steps governing healing with or without fibrosis within the same microenvironment are unclear. After acute kidney injury (AKI), injured proximal tubular epithelial cells activate SOX9 for self-restoration. Using a multimodal approach for a head-to-head comparison of injury-induced SOX9 lineages, we identified a dynamic SOX9 switch in repairing epithelia. Lineages that regenerated epithelia silenced SOX9 and healed without fibrosis (SOX9 on-off ). By contrast, lineages with unrestored apicobasal polarity maintained SOX9 activity in sustained efforts to regenerate, which were identified as a SOX9 on-on Cadherin6 pos cell state. These reprogrammed cells generated substantial single-cell WNT activity to provoke a fibroproliferative response in adjacent fibroblasts, driving AKI to chronic kidney disease. Transplanted human kidneys displayed similar SOX9/CDH6/WNT2B responses. Thus, we have uncovered a sensor of epithelial repair status, the activity of which determines regeneration with or without fibrosis.
- 23 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 383 (6685) , eadd6371
Top Cited PapersSOX9 switch links regeneration to fibrosis at the single-cell level in mammalian kidneys
The steps governing healing with or without fibrosis within the same microenvironment are unclear. After acute kidney injury (AKI), injured proximal tubular epithelial cells activate SOX9 for self-restoration. Using a multimodal approach for a head-to-head comparison of injury-induced SOX9 lineages, we identified a dynamic SOX9 switch in repairing epithelia. Lineages that regenerated epithelia silenced SOX9 and healed without fibrosis (SOX9 on-off ). By contrast, lineages with unrestored apicobasal polarity maintained SOX9 activity in sustained efforts to regenerate, which were identified as a SOX9 on-on Cadherin6 pos cell state. These reprogrammed cells generated substantial single-cell WNT activity to provoke a fibroproliferative response in adjacent fibroblasts, driving AKI to chronic kidney disease. Transplanted human kidneys displayed similar SOX9/CDH6/WNT2B responses. Thus, we have uncovered a sensor of epithelial repair status, the activity of which determines regeneration with or without fibrosis.